Welcome to Glycemicon.
Glycemicon`s efforts are focused on the discovery, development and commercialization of innovative and novel products to prevent and treat elevations in blood sugar levels, the hallmark of type 2 diabetes and pre-diabetes. The company`s first product induces the creation of new fat cells, resulting in a more effective removal of sugar and fat from the circulation. The compound is naturally occurring in humans and found in food products, allowing Glycemicon to develop it as medical food, a form of prescribed healthcare nutrition that has to be monitored by a physician. As a spin-off company from the Federal Institute of Technology/ETH Zürich, we combine strong expertise in adipose tissue biology and diabetes with top-notch synthetic chemistry of natural products and small molecules. Close interaction with the Laboratory of Translational Nutritional Biology and the Laboratory of Organic Chemistry at the ETH will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of obesity and type 2 diabetes. The name Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels which is the aim of each and every diabetic patient.
substances and products for the food and pharmaceutical industry